RxDoctor Payments Data

Andrew Ebner

Physician Assistant · Corbin, KYNPI 1225709280

Payments from drug & device makers

$2,845in general payments, 2019–2025

Across 148 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$764
  • Alkermes, Inc.$497
  • Teva Pharmaceuticals USA, Inc.$345
  • AbbVie$227
  • Neurocrine Biosciences, Inc.$221
  • Otsuka America Pharmaceutical, Inc.$181
  • plus $611 from 8 others

What the payments were for

  • Food & beverage$2,67394%
  • Education$1726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,845 in reported general payments places this provider in the 80th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$7,789
Medicare patients
39
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$103,296
VraylarCariprazine Hcl68$98,707
LybalviOlanzapine/Samidorphan Malate34$52,522
Invega SustennaPaliperidone Palmitate20$46,335
CaplytaLumateperone Tosylate18$28,709
Lurasidone Hcl60$20,670
Paliperidone ErPaliperidone72$14,651
Aripiprazole87$4,004
Olanzapine97$2,209
Quetiapine Fumarate179$1,737
Perphenazine12$1,536
Atomoxetine Hcl21$1,534
Buspirone Hcl153$1,496
Venlafaxine Hcl ErVenlafaxine Hcl116$1,434
Vilazodone Hcl22$1,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$221$103,29613 claims
AbbVieVraylar$227$98,70768 claims
Alkermes, Inc.Lybalvi$497$52,52234 claims
Johnson & JohnsonInvega Sustenna$173$46,33520 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$764$28,70918 claims
Almatica Pharma LLCSertraline Hcl$23$966196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →